Method for separating 2-alkylanthracenes and use thereof for producing hydrogen peroxide
US-12391633-B2 · Aug 19, 2025 · US
Separation; Purification; Stabilisation; Use of additives
Separation; Purification; Stabilisation; Use of additives · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07C46/10 |
| Official title | Separation; Purification; Stabilisation; Use of additives |
| Display label | Separation; Purification; Stabilisation; Use of additives |
| Total patents | 38 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 8 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Method for storing reduced coenzyme q10
US-2025100959-A1 · Mar 27, 2025 · US
Method for storing reduced coenzyme q10
US-2025082585-A1 · Mar 13, 2025 · US
Method for storing reduced coenzyme q10
US-2025059124-A1 · Feb 20, 2025 · US
Process for preparing a Lawsonia inermis extract
US-11987708-B2 · May 21, 2024 · US
Production method for reduced coenzyme q10 form-ii type crystal or crystalline solid thereof
US-2024158330-A1 · May 16, 2024 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2023339835-A1 · Oct 26, 2023 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-11746077-B2 · Sep 5, 2023 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-11667596-B2 · Jun 6, 2023 · US
Production method for crystal of reduced coenzyme Q10 having excellent stability
US-11498893-B2 · Nov 15, 2022 · US
Discovery of potent [alpha]-glucosidase inhibitors from Heterophragma adenophyllum
US-11452708-B2 · Sep 27, 2022 · US
Discovery of potent [alpha]-glucosidase inhibitors from heterophragma adenophyllum
US-2022249428-A1 · Aug 11, 2022 · US
Method for extracting coenzyme Q10 and phospholipid from coenzyme Q10 fermentation bacterial powder
US-11390893-B2 · Jul 19, 2022 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2022220054-A1 · Jul 14, 2022 · US
Process for preparing a lawsonia inermis extract
US-2022204776-A1 · Jun 30, 2022 · US
Method for separating 2-alkylanthracenes and use thereof for producing hydrogen peroxide
US-2022177392-A1 · Jun 9, 2022 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2022106248-A1 · Apr 7, 2022 · US
Production method for crystal of reduced coenzyme q10 having excellent stability
US-2021355059-A1 · Nov 18, 2021 · US
2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-11174212-B2 · Nov 16, 2021 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2021276937-A1 · Sep 9, 2021 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07C46/10?
- CPC C07C46/10 is the Cooperative Patent Classification code for “Separation; Purification; Stabilisation; Use of additives.”
- How many patents are filed under CPC C07C46/10 (Separation; Purification; Stabilisation; Use of additives)?
- Our database includes 38 publications tagged with this CPC code.
- Is patent activity under CPC C07C46/10 growing?
- Publication counts under this code: 2 in 2024 vs 4 in 2025 (latest complete years).